Drug Type Small molecule drug |
Synonyms SL 901 |
Target |
Action inhibitors |
Mechanism PI3K family inhibitors(Phosphatidylinositol 3-kinase family inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | Italy | 30 Jan 2022 | |
Advanced Malignant Solid Neoplasm | Phase 1 | United Kingdom | 19 Mar 2021 | |
Lung Cancer | Phase 1 | - | - |
Phase 1 | 20 | (Cohort 1: SL-901 20 mg) | ydtjarlcah = qvcxtwcbiw dilopgshqg (kkoabaougu, udjafnzlvc - rjevwcntsl) View more | - | 25 Mar 2025 | ||
(Cohort 2: SL-901 40 mg) | ydtjarlcah = xjxmjogxhd dilopgshqg (kkoabaougu, uktvhmldui - nxszkfgxhq) View more |